Alterity Therapeutics Ltd ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
23.5%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.57next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents (AUD) Quarterly44.5MTarget: Maintain sufficient runway to complete Phase 3 initiation and advance partnering discussions
ATH434 Phase 2 Efficacy - MuSyCA Composite Scale Treatment Effect (Points) Annually-4.0Target: Demonstrate statistically and clinically significant slowing of functional decline in Phase 3
Watch Items
- End-of-Phase 2 FDA Meeting for ATH434 in Multiple System Atrophy (MSA)Trigger: Mid-year 2026Action: Finalize regulatory strategy and secure alignment on the pivotal Phase 3 trial design
- Strategic Collaboration and Licensing Partnerships for ATH434Trigger: Ongoing discussions with pharmaceutical companiesAction: Leverage positive Phase 2 data to secure non-dilutive funding or co-development agreements
Research as of 19 Jun 2026